Profile data is unavailable for this security.
About the company
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.
- Revenue in USD (TTM)80.33m
- Net income in USD29.34m
- Incorporated2013
- Employees97.00
- LocationTheravance Biopharma IncUGLAND HOUSE, SOUTH CHURCH STREETGEORGE TOWN KY1-1104Cayman IslandsCYM
- Phone+1 3456 508086000
- Websitehttps://www.theravance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. | 296.15m | 24.02m | 582.12m | 100.00 | 33.11 | -- | 22.48 | 1.97 | 0.1078 | 0.1078 | 1.86 | -1.61 | 0.792 | -- | 4.60 | 2,961,510.00 | 6.42 | -8.59 | 10.29 | -10.50 | -- | -- | 8.11 | -15.83 | -- | 4.14 | 1.81 | -- | -15.72 | -5.33 | 2,629.21 | -25.72 | -55.00 | -- |
| Rigel Pharmaceuticals Inc | 282.08m | 113.30m | 628.40m | 162.00 | 5.61 | 5.34 | 5.43 | 2.23 | 6.17 | 6.17 | 15.36 | 6.48 | 1.48 | 2.15 | 7.37 | 1,741,210.00 | 59.33 | -16.62 | 97.15 | -28.36 | 93.10 | 95.63 | 40.17 | -16.88 | 2.14 | 25.77 | 0.3368 | -- | 53.38 | 24.77 | 169.69 | -- | -22.92 | -- |
| Sinovac Biotech Ltd | 429.20m | -130.73m | 639.90m | 3.04k | -- | -- | -- | 1.49 | -1.31 | -1.31 | 4.31 | 86.81 | 0.0322 | 0.2019 | 1.08 | 141,325.00 | -2.23 | 36.14 | -3.30 | 58.37 | 92.09 | 90.77 | -69.19 | 65.87 | 11.24 | -- | 0.0262 | -- | -69.97 | 14.31 | -198.16 | -- | 91.80 | -- |
| ASP Isotopes Inc | 8.38m | -105.56m | 688.11m | 136.00 | -- | 6.93 | -- | 82.08 | -1.43 | -1.43 | 0.1124 | 0.7932 | 0.0541 | 8.86 | 0.884 | 61,642.43 | -68.21 | -- | -85.13 | -- | 23.00 | -- | -1,261.23 | -- | 6.10 | -0.6787 | 0.5382 | -- | 857.03 | -- | -115.60 | -- | -- | -- |
| Esperion Therapeutics Inc | 303.80m | -105.83m | 781.74m | 304.00 | -- | -- | -- | 2.57 | -0.5358 | -0.5358 | 1.54 | -2.20 | 0.896 | 1.35 | 3.25 | 999,348.70 | -31.21 | -61.82 | -138.14 | -101.31 | 58.20 | 81.27 | -34.84 | -109.30 | 0.7017 | -0.3928 | 4.08 | -- | 185.66 | 17.50 | 75.27 | -- | -19.76 | -- |
| Nika Pharmaceuticals Inc | 0.00 | -51.76k | 785.60m | -- | -- | -- | -- | -- | -0.00005 | -0.00005 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -413.75 | -21,428.06 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -47.74 | -- | -- | -- |
| Pacira Biosciences Inc | 726.41m | 7.03m | 861.62m | 829.00 | 135.47 | 1.26 | 8.78 | 1.19 | 0.1571 | 0.1571 | 16.19 | 16.86 | 0.5155 | 1.08 | 6.12 | 876,249.70 | 0.4991 | 0.0898 | 0.5891 | 0.1062 | 79.39 | 74.50 | 0.9683 | 0.221 | 3.28 | -- | 0.3494 | 0.00 | 3.63 | 11.07 | 107.07 | -45.44 | -16.51 | -- |
| Phathom Pharmaceuticals Inc | 175.11m | -221.25m | 903.03m | 371.00 | -- | -- | -- | 5.16 | -3.05 | -3.05 | 2.40 | -6.14 | 0.5494 | 5.18 | 3.00 | 471,994.60 | -69.41 | -77.19 | -105.43 | -94.72 | 87.09 | -- | -126.35 | -475.57 | 1.69 | -2.47 | 3.95 | -- | 216.93 | -- | 33.82 | -- | -26.11 | -- |
| Amphastar Pharmaceuticals Inc | 719.89m | 98.09m | 953.23m | 1.98k | 10.33 | 1.22 | 6.16 | 1.32 | 2.03 | 2.03 | 14.93 | 17.28 | 0.449 | 2.20 | 5.14 | 364,315.30 | 6.12 | 9.83 | 6.82 | 11.35 | 49.46 | 50.52 | 13.63 | 18.26 | 2.90 | 8.36 | 0.4362 | 0.00 | -1.65 | 15.53 | -38.51 | 133.84 | 1.87 | -- |
| Theravance Biopharma Inc | 80.33m | 29.34m | 960.24m | 97.00 | 33.68 | 4.13 | 30.98 | 11.95 | 0.5626 | 0.5626 | 1.59 | 4.59 | 0.2082 | -- | 4.58 | 828,113.40 | 7.61 | -34.51 | 8.26 | -40.08 | -- | -- | 36.53 | -254.51 | -- | -- | 0.1216 | -- | 12.12 | -2.59 | -2.22 | -- | -36.34 | -- |
| Xeris Biopharma Holdings Inc | 266.14m | -15.64m | 998.86m | 394.00 | -- | -- | -- | 3.75 | -0.1033 | -0.1033 | 1.67 | -0.0052 | 0.77 | 0.7301 | 5.61 | 675,474.60 | -4.52 | -31.61 | -6.46 | -42.28 | 84.56 | 79.76 | -5.88 | -77.77 | 1.35 | 0.3853 | 1.00 | -- | 23.89 | 136.89 | 11.92 | -- | -4.75 | -- |
| Day One Biopharmaceuticals Inc | 158.18m | -107.32m | 1.07bn | 178.00 | -- | 2.42 | -- | 6.77 | -1.04 | -1.04 | 1.53 | 4.28 | 0.2901 | 3.57 | 7.79 | 888,662.90 | -19.68 | -32.37 | -22.44 | -35.43 | 89.12 | -- | -67.85 | -209.67 | 7.91 | -- | 0.00 | -- | 20.60 | -- | -12.38 | -- | 110.70 | -- |
| Precigen Inc | 6.31m | -425.87m | 1.28bn | 143.00 | -- | 30.59 | -- | 203.02 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Collegium Pharmaceutical Inc | 780.57m | 62.87m | 1.32bn | 423.00 | 24.32 | 4.37 | 4.57 | 1.69 | 1.71 | 1.71 | 20.54 | 9.51 | 0.4702 | 8.30 | 3.55 | 1,845,312.00 | 3.79 | 3.89 | 5.30 | 5.96 | 59.35 | 56.32 | 8.05 | 8.34 | 1.48 | 2.65 | 0.7285 | 0.00 | 23.62 | 20.28 | -9.13 | 18.64 | -65.83 | -- |
Data as of Mar 03 2026. Currency figures normalised to Theravance Biopharma Inc's reporting currency: US Dollar USD
66.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Madison Avenue Partners LPas of 31 Dec 2025 | 9.51m | 18.77% |
| Weiss Asset Management LPas of 31 Dec 2025 | 7.46m | 14.72% |
| Newtyn Management LLCas of 31 Dec 2025 | 4.30m | 8.49% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 3.25m | 6.42% |
| Irenic Capital Management LPas of 31 Dec 2025 | 2.76m | 5.45% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.10m | 4.14% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 1.26m | 2.49% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 1.17m | 2.30% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.10m | 2.18% |
| Arrowstreet Capital LPas of 31 Dec 2025 | 963.26k | 1.90% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
